RESUMO
The persistent Müllerian duct syndrome (PMDS) is defined by the persistence of Müllerian derivatives in an otherwise normally virilized 46,XY male. It is usually caused by mutations in either the anti-Müllerian hormone (AMH) or AMH receptor type 2 (AMHR2) genes. We report the first cases of PMDS resulting from a microdeletion of the chromosomal region 12q13.13, the locus of the gene for AMHR2. One case involved a homozygous microdeletion of five exons of the AMHR2 gene. In the second case, the whole AMHR2 gene was deleted from the maternally inherited chromosome. The patient's paternal allele carried a stop mutation, which was initially thought to be homozygous by Sanger sequencing. Diagnostic methods are discussed, with an emphasis on comparative genomic hybridization and targeted massive parallel sequencing.
Assuntos
Receptores de Peptídeos , Receptores de Fatores de Crescimento Transformadores beta , Hormônio Antimülleriano/genética , Hibridização Genômica Comparativa , Transtorno 46,XY do Desenvolvimento Sexual , Humanos , Masculino , Receptores de Peptídeos/genética , Receptores de Fatores de Crescimento Transformadores beta/genéticaRESUMO
BACKGROUND: We report a novel mutation in a case of Persistent Mullerian Duct Syndrome (PMDS). PMDS is characterized by the persistence of female reproductive organs derivatives in a 46,XY subject due to the failure of the Mullerian duct to regress in utero. To date, 53 different mutations of the anti-Mullerian hormone (AMH) gene, including the present one, have been identified. CLINICAL CASE: A 2-week-old male presented with bilateral cryptorchidism and normal male external genitalia. His karyotype was 46,XY. hCG stimulation test was normal. At age 1 year and 4 months, he underwent laparoscopic surgery which revealed a uterus and fallopian tubes. The anti-Mullerian hormone (AMH) level was undetectable (<0.01 ng/mL). Diagnosis of Persistent Mullerian Duct Syndrome, probably due to an AMH mutation, was made. GENETIC STUDIES: A unique homozygous T to G base substitution was found at position 2219, near the middle of the exon 5, changing codon CTG to CGG in anti-Mullerian hormone (AMH) gene. This mutation causes leucine to be converted to arginine at position 426 belonging to a (L)RA(L)LLLKALQ highly conserved sequence in the AMH gene. Both parents are heterozygous for the mutation. CONCLUSION: Persistent Mullerian Duct Syndrome (PMDS) is a rare cause of bilateral cryptorchidism, when in doubt the existence of Mullerian derivatives should be explored by laparoscopy. Assay of serum AMH helps to distinguish between mutations of AMH and AMH receptor. If serum AMH is very low or undetectable, sequencing of the AMH gene usually confirms the presence of a mutation.
Assuntos
Hormônio Antimülleriano/genética , Criptorquidismo/genética , Transtorno 46,XY do Desenvolvimento Sexual/genética , Criptorquidismo/diagnóstico , Transtorno 46,XY do Desenvolvimento Sexual/diagnóstico , Humanos , Recém-Nascido , Masculino , Mutação PuntualRESUMO
Male patients with an extra sex chromosome or autosome are expected to present primary hypogonadism at puberty owing to meiotic germ-cell failure. Scarce information is available on trisomy 21, a frequent autosomal aneuploidy. Our objective was to assess whether trisomy 21 presents with pubertal-onset, germ-cell specific, primary hypogonadism in males, or whether the hypogonadism is established earlier and affects other testicular cell populations. We assessed the functional status of the pituitary-testicular axis, especially Sertoli cell function, in 117 boys with trisomy 21 (ages: 2months-20year). To compare with an adequate control population, we established reference levels for serum anti-Müllerian hormone (AMH) in 421 normal males, from birth to adulthood, using a recently developed ultrasensitive assay. In trisomy 21, AMH was lower than normal, indicating Sertoli cell dysfunction, from early infancy, independently of the existence of cryptorchidism. The overall prevalence rate of AMH below the 3rd percentile was 64.3% in infants with trisomy 21. Follicle-stimulating hormone was elevated in patients <6months and after pubertal onset. Testosterone was within the normal range, but luteinizing hormone was elevated in most patients <6months and after pubertal onset, indicating a mild Leydig cell dysfunction. We conclude that in trisomy 21, primary hypogonadism involves a combined dysfunction of Sertoli and Leydig cells, which can be observed independently of cryptorchidism soon after birth, thus prompting the search for new hypotheses to explain the pathophysiology of gonadal dysfunction in autosomal trisomy.
Assuntos
Hormônio Antimülleriano/sangue , Síndrome de Down/fisiopatologia , Hipogonadismo/fisiopatologia , Adolescente , Adulto , Criança , Pré-Escolar , Síndrome de Down/complicações , Hormônio Foliculoestimulante/sangue , Humanos , Hipogonadismo/sangue , Hipogonadismo/etiologia , Lactente , Recém-Nascido , Células Intersticiais do Testículo/fisiologia , Hormônio Luteinizante/sangue , Masculino , Tamanho do Órgão , Células de Sertoli/fisiologia , Testículo/anatomia & histologia , Testosterona/sangueRESUMO
Anti-Müllerian hormone (AMH), responsible for the regression of Müllerian ducts, is strongly expressed by eutherian fetal and postnatal Sertoli cells. Both AMH and testosterone levels are high during the period of fetal reproductive tract virilization which occurs largely in utero in eutherian mammals. Taking advantage of the fact that differentiation of the urogenital tract occurs after birth in marsupials, we studied the ontogeny and regulation of AMH in the tammar wallaby testis and related it to the expression of the androgen receptor in Sertoli cells. Testicular AMH expression was high between days 10-30 post partum, then fell to basal levels by day 60 and remained low until day 90, the oldest age examined. AMH expression was repressed by treatment of male pouch young with the potent androgen androstanediol. Thus, in the tammar, AMH expression decreases in response to androgen at the time of initial urogenital masculinization, in contrast to the situation in humans in which AMH is repressed by testosterone only at the time of puberty. The difference might be explained by the timing of androgen receptor expression which appears in tammar Sertoli cells at around day 40 of pouch life but only at a later developmental stage in eutherians.
Assuntos
Hormônio Antimülleriano/genética , Regulação para Baixo/genética , Macropodidae/genética , Receptores Androgênicos/metabolismo , Células de Sertoli/metabolismo , Sistema Urogenital/metabolismo , Virilismo/genética , Androstano-3,17-diol/farmacologia , Animais , Hormônio Antimülleriano/metabolismo , Regulação para Baixo/efeitos dos fármacos , Feminino , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Imuno-Histoquímica , Hibridização In Situ , Macropodidae/embriologia , Masculino , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Células de Sertoli/citologia , Células de Sertoli/efeitos dos fármacos , Fatores de Tempo , Sistema Urogenital/efeitos dos fármacosRESUMO
Today, serum antimullerian hormone (AMH) is considered as an interesting marker of fertility potential in women to determine follicular status and in men to evaluate testicular function. We study analytical and clinical characteristics of two AMH commercialized immunoassays: Immunotech and DSL methods. The detection limits (close to 0.13 ng/mL), functional sensitivities (close to 0.30 ng/mL) are equivalent, and imprecision results are acceptable for entirely manual assays. The Immunotech method is linear within the calibration range (up to 21 ng/mL) and the DSL method presents a lack of linearity making it accurate only up to 11 ng/mL (and not up to 14 ng/mL as it is indicated by the manufacturer). The two methods allow to measure human AMH, don't cross react with TGF-beta superfamily proteins and the DSL immunoassay recognize mouse (25%), rat (68%) and calf (100%) AMH. The comparison between the two methods (from 0.3 to 200 ng/mL) shows a good correlation (r = 0.979) with not statistically different results (p = 0.31). From a clinical point of view, the two methods allow the evaluation of follicular status in normo-ovulatory women and in women with polycystic ovary syndrome. Results are in agreement with studies showing that AMH serum concentration is strongly correlated with the number of antral follicles. In conclusion, the Immunotech method seems to be more efficient than the DSL method even if the two methods are suitable for clinical applications needing AMH measurements.
Assuntos
Hormônio Antimülleriano/sangue , Transtornos do Desenvolvimento Sexual/sangue , Ensaio de Imunoadsorção Enzimática/métodos , Hirsutismo/sangue , Hiperandrogenismo/sangue , Infertilidade Feminina/sangue , Distúrbios Menstruais/sangue , Síndrome do Ovário Policístico/sangue , Adulto , Amenorreia/sangue , Criança , Feminino , Humanos , Modelos Lineares , Masculino , Ciclo Menstrual , Oligomenorreia/sangue , Reprodutibilidade dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Estatísticas não ParamétricasRESUMO
Persistent Müllerian Duct Syndrome (PMDS) is a rare disorder of the anti-mullerian hormone (AMH) synthesis or receptor, which due to the visual contrast of normal masculine external genitalia and female internal genitalia can raise confusion, sometimes during surgery for cryptorchidism or hernia inguinalis. For an acute and accurate analysis of such a situation a thorough knowledge of gonadal embryology is mandatory. The diagnosis is made on finding Müllerian structures in an individual with complete virilization without signs of hypocortisolism or exposition to maternal androgens during foetal life. Karyotyping and gonadal biopsy provide additional information to confirm the diagnosis. As the risk of malignant transformation is not clear, orchidopexy is advised in patients with cryptorchidism, with lifelong palpatory follow-up. In case of urologic symptoms, surgical removal of the Müllerian remnants can be considered, with careful attention for the vulnerable ductus deferens. Despite optimal treatment the prognosis regarding fertility remain uncertain.
Assuntos
Transtornos do Desenvolvimento Sexual/diagnóstico , Ductos Paramesonéfricos/anormalidades , Hormônio Antimülleriano/metabolismo , Criptorquidismo/diagnóstico , Diagnóstico Diferencial , Transtornos do Desenvolvimento Sexual/fisiopatologia , Hérnia Inguinal/diagnóstico , Humanos , Lactente , Recém-Nascido , Masculino , Doenças Raras , SíndromeRESUMO
Anti-Müllerian hormone belongs to the TGFbeta family whose members exert their effects by signaling through two related serine/threonine kinase receptors. Mutations of the anti-Müllerian hormone type II receptor occur naturally, causing the persistent Müllerian duct syndrome. In a family with two members with persistent Müllerian duct syndrome and one normal sibling, we detected two novel mutations of the anti-Müllerian hormone type II receptor gene. One, transmitted by the mother to her three sons, is a deletion of a single base leading to a stop codon, causing receptor truncation after the transmembrane domain. The other, a missense mutation in the substrate-binding site of the kinase domain, is transmitted by the father to the two sons affected by persistent Müllerian duct syndrome, indicating a recessive autosomal transmission as in other cases of persistent Müllerian duct syndrome. Truncating mutations in receptors of the TGFbeta family exert dominant negative activity, which was seen only when each of the mutant anti-Müllerian hormone receptors was overexpressed in an anti-Müllerian hormone-responsive cell line. We conclude that assessment of dominant activity in vitro, which usually involves overexpression of mutant genes, does not necessarily produce information applicable to clinical conditions, in which mutant and endogenous genes are expressed on a one to one basis.
Assuntos
Glicoproteínas , Inibidores do Crescimento/genética , Ductos Paramesonéfricos/fisiologia , Receptores de Peptídeos/genética , Hormônios Testiculares/genética , Fator de Crescimento Transformador beta/fisiologia , Animais , Hormônio Antimülleriano , Biotina , Northern Blotting , Células COS , Criança , Clonagem Molecular , Regulação para Baixo/genética , Genes Reporter/genética , Humanos , Masculino , Mutagênese Sítio-Dirigida/genética , Linhagem , Polimorfismo Conformacional de Fita Simples , Receptores de Superfície Celular/genética , Receptores de Fatores de Crescimento Transformadores beta , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Síndrome , Transfecção , Fator de Crescimento Transformador beta/genéticaRESUMO
Anti-Müllerian hormone inhibits granulosa cell growth and function. Both anti-Müllerian hormone and its type II receptor are expressed in normal granulosa cells. We show by histologic and molecular analyses that ovarian tumors developing in transgenic mice, obtained by targeted oncogenesis using an anti-Müllerian hormone promoter-SV40 oncogene construct, are of granulosa-cell origin. Because tissue-specific, cell-surface molecules are of particular interest for the analysis and treatment of tumors, we examined the expression of anti-Müllerian hormone type II receptor in the ovaries of these transgenic mice. We demonstrate that the anti-Müllerian hormone type II receptor is expressed not only in normal ovarian follicles, but also in granulosa cell tumors. Using a cell line derived from one of these tumors, we show that the anti-Müllerian hormone type II receptor protein is present on the surface of tumor cells and binds anti-Müllerian hormone. Furthermore, we show that the anti-Müllerian hormone receptor is functional in the granulosa tumor cell line, with anti-Müllerian hormone treatment inducing selective activation of Smad1. In conclusion, in this study we present a new murine transgenic model of granulosa cell tumors of the ovary and, using this model, we demonstrate for the first time cell-surface expression of a highly tissue-specific molecule, anti-Müllerian hormone type II receptor, as well as the selective activation of Smad proteins by anti-Müllerian hormone, in granulosa tumor cells.
Assuntos
Glicoproteínas , Tumor de Células da Granulosa/metabolismo , Neoplasias Ovarianas/metabolismo , Receptores de Peptídeos/metabolismo , Animais , Hormônio Antimülleriano , Biomarcadores Tumorais/metabolismo , Proteínas de Ligação a DNA/fisiologia , Feminino , Tumor de Células da Granulosa/patologia , Tumor de Células da Granulosa/fisiopatologia , Inibidores do Crescimento/genética , Camundongos , Camundongos Transgênicos/genética , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/fisiopatologia , Receptores de Peptídeos/fisiologia , Receptores de Fatores de Crescimento Transformadores beta , Proteínas Smad , Proteína Smad1 , Proteína Smad2 , Proteína Smad4 , Hormônios Testiculares/genética , Transativadores/fisiologia , Células Tumorais CultivadasRESUMO
Regression of the Müllerian duct in the male embryo is one unequivocal effect of anti-Müllerian hormone, a glycoprotein secreted by the Sertoli cells of the testis. This hormone induces ductal epithelial regression through a paracrine mechanism originating in periductal mesenchyme. To probe the mechanisms of action of anti-Müllerian hormone, we have studied the sequence of cellular and molecular events involved in duct regression. Studies were performed in male rat embryos and in transgenic mice overexpressing or lacking anti-Müllerian hormone, both in vivo and in vitro. Anti-Müllerian hormone causes regression of the cranial part of the Müllerian duct whereas it continues to grow caudally. Our work shows that this pattern of regression is correlated with a cranial to caudal gradient of anti-Müllerian hormone receptor protein, followed by a wave of apoptosis spreading along the Müllerian duct as its progresses caudally. Apoptosis is also induced by AMH in female Müllerian duct in vitro. Furthermore, apoptotic indexes are increased in Müllerian epithelium of transgenic mice of both sexes overexpressing the human anti-Müllerian hormone gene, exhibiting a positive correlation with serum hormone concentration. Inversely, apoptosis is reduced in male anti-Müllerian hormone-deficient mice. We also show that apoptosis is a decisive but not sufficient process, and that epitheliomesenchymal transformation is an important event of Müllerian regression. The most striking result of this study is that anti-Müllerian hormone action in peri-Müllerian mesenchyme leads in vivo and in vitro to an accumulation of cytoplasmic beta-catenin. The co-localization of beta-catenin with lymphoid enhancer factor 1 in the nucleus of peri-Müllerian mesenchymal cells, demonstrated in primary culture, suggests that overexpressed beta-catenin in association with lymphoid enhancer factor 1 may alter transcription of target genes and may lead to changes in mesenchymal gene expression and cell fate during Müllerian duct regression. To our knowledge, this is the first report that beta-catenin, known for its role in Wnt signaling, may mediate anti-Müllerian hormone action.
Assuntos
Proteínas do Citoesqueleto/fisiologia , Glicoproteínas , Inibidores do Crescimento/fisiologia , Ductos Paramesonéfricos/embriologia , Hormônios Testiculares/fisiologia , Transativadores , Animais , Hormônio Antimülleriano , Apoptose , Membrana Basal/metabolismo , Células Cultivadas , Proteínas de Ligação a DNA/metabolismo , Epitélio/metabolismo , Feminino , Fator 1 de Ligação ao Facilitador Linfoide , Masculino , Mesoderma/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Ductos Paramesonéfricos/metabolismo , Técnicas de Cultura de Órgãos , Ratos , Receptores de Peptídeos/biossíntese , Receptores de Peptídeos/fisiologia , Receptores de Fatores de Crescimento Transformadores beta , Células Estromais/metabolismo , Fatores de Transcrição/metabolismo , beta CateninaRESUMO
Granulosa cell tumors (GCT) are ovarian neoplasms that tend to recur and spread in the pelvis and the abdomen several years after the initial treatment. Anti-Mülerian hormone (AMH) is a reliable serum marker of these tumors. To enhance the availability and the sensitivity of serum AMH determination, we developed an ultrasensitive enzyme-linked immunosorbent assay. In this work we compare the results of serum AMH levels, obtained using the ultrasensitive and the traditional assays, in 31 patients with ovarian GCT followed up for up to 7 yr. The ultrasensitive enzyme-linked immunosorbent assay has a significantly higher sensitivity than the traditional one. This resulted in the detection of low serum AMH levels, which were undetectable with the traditional assay, in several cases including one patient in whom a recurrence of a GCT had developed and two patients in whom the treatment had not been completely successful. These cases highlight the importance of the availability of a highly sensitive assay allowing evaluation with high precision of the results of treatment and to detect the recurrences of GCT at an early, preclinical stage.
Assuntos
Ensaio de Imunoadsorção Enzimática/métodos , Glicoproteínas , Tumor de Células da Granulosa/sangue , Inibidores do Crescimento/sangue , Neoplasias Ovarianas/sangue , Hormônios Testiculares/sangue , Adolescente , Adulto , Hormônio Antimülleriano , Criança , Estudos de Avaliação como Assunto , Feminino , Seguimentos , Humanos , Valores de Referência , Sensibilidade e EspecificidadeRESUMO
The persistent müllerian duct syndrome is a rare, autosomal recessive disorder, characterized by the persistence of müllerian duct derivatives-uterus and fallopian tubes-in genetic males otherwise normally virilized. We have collected DNA from 69 families with this syndrome. In 45%, a mutation of the anti-müllerian hormone (AMH) gene was detected; 52% were homozygous. The level of circulating AMH was extremely low in the great majority of patients, even before puberty, when AMH levels are normally high. Single-strand conformation polymorphism (SSCP)-polymerase chain reaction (PCR) was a very effective screening method. In 39% of families, characterized by an AMH level normal for the age of the patient, a mutation of the type II receptor of AMH was detected by automatic sequencing, because SSCP-PCR was not very effective. Forty-eight percent of the mutations were homozygous. A 27-base-pair deletion in exon 10 was noted in 45% of the families. When this very common mutation is not taken into account, the proportion of recurrent mutations is 42% for the AMH gene and 33% for the AMH receptor type II gene. In 16% of families, no mutation of either the AMH or the AMH receptor gene was detectable; this group may correspond to mutations of unknown genes involved in AMH processing or in downstream AMH transduction.
Assuntos
Doenças dos Genitais Masculinos/etiologia , Doenças dos Genitais Masculinos/genética , Glicoproteínas , Ductos Paramesonéfricos/anormalidades , Hormônio Antimülleriano , Família , Genes Recessivos/genética , Testes Genéticos , Doenças dos Genitais Masculinos/diagnóstico , Inibidores do Crescimento/biossíntese , Inibidores do Crescimento/deficiência , Inibidores do Crescimento/genética , Homozigoto , Humanos , Masculino , Ductos Paramesonéfricos/metabolismo , Mutação , Fenótipo , Reação em Cadeia da Polimerase , Polimorfismo Conformacional de Fita Simples , Receptores de Peptídeos/genética , Receptores de Fatores de Crescimento Transformadores beta , Células de Sertoli/metabolismo , Hormônios Testiculares/biossíntese , Hormônios Testiculares/deficiência , Hormônios Testiculares/genéticaRESUMO
In mammals, anti-Müllerian hormone (AMH) is produced by Sertoli cells from the onset of testicular differentiation and by granulosa cells only after birth. SOX9, a transcription factor related to the testis-determining factor SRY, is expressed in mouse testis 1 day before AMH. To determine the relationship between AMH and SOX9 in birds, we cloned the AMH promoter in search of SOX9 response elements, and we compared the expression of AMH and SOX9 in the gonads of chick embryos using in situ hybridization. Potential SOX response elements were found in the AMH promoter; however, AMH is expressed in both sexes at stage 25, 1 day before the first SOX9 transcripts appear in the male gonads. SOX9 is never expressed in the female. These results do not support the hypothesis that SOX9 could trigger the expression of testicular AMH in the chick but does not exclude a later role in testis development.
Assuntos
Glicoproteínas , Gônadas/embriologia , Gônadas/metabolismo , Inibidores do Crescimento/biossíntese , Proteínas de Grupo de Alta Mobilidade/biossíntese , Ductos Paramesonéfricos/metabolismo , Diferenciação Sexual/fisiologia , Hormônios Testiculares/biossíntese , Testículo/enzimologia , Testículo/metabolismo , Fatores de Transcrição/biossíntese , Animais , Hormônio Antimülleriano , Sequência de Bases , Embrião de Galinha , Mapeamento Cromossômico , Clonagem Molecular , Feminino , Gônadas/química , Inibidores do Crescimento/análise , Inibidores do Crescimento/genética , Inibidores do Crescimento/fisiologia , Proteínas de Grupo de Alta Mobilidade/fisiologia , Hibridização in Situ Fluorescente , Masculino , Dados de Sequência Molecular , Ductos Paramesonéfricos/química , Ductos Paramesonéfricos/fisiologia , Ovário/química , Ovário/enzimologia , Ovário/metabolismo , Sequências Reguladoras de Ácido Nucleico/genética , Fatores de Transcrição SOX9 , Análise de Sequência de DNA , Hormônios Testiculares/análise , Hormônios Testiculares/genética , Hormônios Testiculares/fisiologia , Testículo/química , Fatores de Transcrição/fisiologiaRESUMO
In the human male fetus, testes develop by the 7th week and begin to secrete two hormones: anti-müllerian hormone (AMH) induces the regression of müllerian ducts, the anlagen of the uterus, fallopian tubes and upper vagina, upon binding to a specific membrane receptor, whereas testosterone induces the differentiation of the wolffian ducts into the epididymes, vasa deferentia and seminal vesicles. In some target tissues, testosterone is converted to dihydrotestosterone, which is responsible for masculinization of the urogenital sinus and external genitalia. Both androgens act upon binding to the same nuclear receptor. In the absence of AMH and androgen action, or example in the female or in abnormal male differentiation, the internal and external genital primordia differentiate following the female pathway, even in the absence of ovaries. In males, an impaired function of the AMH-dependent pathway results in the persistent müllerian duct syndrome, a disorder characterized by the presence of uterus and fallopian tubes in otherwise normally virilized boys. Several mutations found in the AMH and AMH-receptor genes explain the pathophysiology of this syndrome.
Assuntos
Genitália Feminina/embriologia , Genitália Masculina/embriologia , Glicoproteínas , Diferenciação Sexual/genética , Hormônio Antimülleriano , Criança , Pré-Escolar , Proteínas de Ligação a DNA/genética , Feminino , Fatores de Transcrição Fushi Tarazu , Genitália Feminina/fisiologia , Genitália Masculina/fisiologia , Disgenesia Gonadal/embriologia , Disgenesia Gonadal/fisiopatologia , Inibidores do Crescimento/metabolismo , Proteínas de Homeodomínio , Humanos , Lactente , Masculino , Ductos Paramesonéfricos/embriologia , Ductos Paramesonéfricos/fisiologia , Receptores Citoplasmáticos e Nucleares , Fator Esteroidogênico 1 , Hormônios Testiculares/metabolismo , Testosterona/metabolismo , Fatores de Transcrição/genética , Ductos Mesonéfricos/embriologia , Ductos Mesonéfricos/fisiologiaRESUMO
Anti-Müllerian hormone (AMH) induces the regression of Müllerian ducts in the male foetus; it is secreted by prepubertal testicular Sertoli cells and repressed at puberty. Using an AMH promoter/Simian virus 40 (SV40) oncogene fusion gene, we generated transgenic mouse lines exhibiting heritable Sertoli cell tumorigenesis. One cell line, derived from an adult male, expressed mRNAs characteristic of mature Sertoli cells, but no AMH. Two other cell lines were obtained from pretumoral testes at 6.5 days. One was cloned to yield SMAT1, whose expression pattern was characteristic of prepubertal Sertoli cells, namely no transferrin and high SF-I and AMH expression. SMAT1 also secretes AMH protein into the culture medium and expresses the AMH receptor. To the best of our knowledge, this is the first Sertoli cell line stably expressing AMH and its receptor. Our results show that, in targeted oncogenesis, the timing of cell line derivation plays a critical role even when using a developmentally regulated promoter.
Assuntos
Glicoproteínas , Inibidores do Crescimento/metabolismo , Receptores de Peptídeos/metabolismo , Células de Sertoli/metabolismo , Hormônios Testiculares/metabolismo , Animais , Hormônio Antimülleriano , Antígenos Transformantes de Poliomavirus/genética , Linhagem Celular , DNA Recombinante/genética , Feminino , Expressão Gênica , Inibidores do Crescimento/genética , Humanos , Masculino , Camundongos , Camundongos Transgênicos , Oncogenes/genética , Neoplasias Ovarianas/genética , Regiões Promotoras Genéticas/genética , RNA Mensageiro/análise , RNA Viral/análise , Receptores de Fatores de Crescimento Transformadores beta , Tumor de Células de Sertoli/genética , Vírus 40 dos Símios/genética , Vírus 40 dos Símios/imunologia , Hormônios Testiculares/genética , Neoplasias Testiculares/genética , Neoplasias Testiculares/patologia , Testículo/química , Células Tumorais CultivadasRESUMO
Anti-Müllerian hormone, a member of the transforming growth factor beta superfamily, produces early regression of Müllerian ducts in the male fetus through binding to a serine/threonine kinase receptor, homologous to type II receptors of the transforming growth factor beta (TGF-beta) family. A splice mutation of this receptor, described in a patient with abnormal retention of Müllerian derivatives, generates two mutant isoforms, one lacking the second exon and the other bearing an insertion of 12 bases between exons 2 and 3. Using hemagglutinin-tagged recombinant receptors, we have visualized wild type and mutant receptors in COS cells by Western blotting and immunoprecipitation. The 82-kDa, endoglycosidase H-insensitive, mature form of the wild type receptor is reduced to 68 kDa by N-glycosidase F treatment. Mutant receptor isoforms, 73 and 63 kDa for the long and short form, respectively, are sensitive to endoglycosidase H, suggesting that they are retained in the endoplasmic reticulum. Indeed, only the wild type receptor was expressed on the cell surface and bound iodinated anti-Müllerian hormone. These results provide a biological explanation for the failure of the mutant receptor to induce Müllerian regression.
Assuntos
Receptores de Peptídeos/metabolismo , Processamento Alternativo , Animais , Células COS , Compartimento Celular , Membrana Celular/metabolismo , Glicosilação , Humanos , Masculino , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Mutação Puntual , Receptores de Peptídeos/genética , Receptores de Fatores de Crescimento Transformadores beta , Relação Estrutura-AtividadeRESUMO
The persistent müllerian duct syndrome, characterized by the lack of regression of müllerian derivatives, uterus and tubes in otherwise normally masculinized males, is a genetically transmitted disorder implicating either anti-müllerian hormone (AMH), a member of the transforming growth factor-beta superfamily, or its type II receptor, a serine/threonine kinase homologous to the receptors of other members of the transforming growth factor-beta superfamily. We have now performed molecular studies in a total of 38 families. The basis of the condition, namely 16 AMH and 16 AMH receptor mutations, was identified in 32 families. The type of genetic defect could be predicted from the level of serum AMH which is very low or undetectable in patients with AMH mutations and at the upper limit of normal in receptor mutations. Whereas AMH mutations are extremely diverse, patients from 10 out of 16 families with receptor mutations had a 27 bp deletion in exon 10 on at least one allele. This deletion is thus implicated in approximately 25% of patients with persistent müllerian duct syndrome. All AMH and AMH receptor mutations were consistent with an autosomal recessive mode of transmission.
Assuntos
Transtornos do Desenvolvimento Sexual/genética , Ductos Paramesonéfricos/anormalidades , Receptores de Peptídeos/genética , Deleção de Sequência , Sequência de Aminoácidos , Sequência de Bases , Criança , Pré-Escolar , Mapeamento Cromossômico , Humanos , Lactente , Recém-Nascido , Masculino , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Polimorfismo Conformacional de Fita Simples , Receptores de Fatores de Crescimento Transformadores beta , SíndromeRESUMO
The persistent Müllerian duct syndrome, characterized by the presence of uterus and tubes in otherwise normally masculinized 46,XY males, is a familial autosomal recessive disorder due to defects of synthesis or action of anti-Müllerian hormone. We have performed molecular studies in a total of 38 families and we have identified the basis of the condition, namely 16 anti-Müllerian hormone and 16 anti-Müllerian hormone receptor mutations, in 32 families.
Assuntos
Transtornos do Desenvolvimento Sexual/genética , Glicoproteínas , Ductos Paramesonéfricos/anormalidades , Hormônio Antimülleriano , Transtornos do Desenvolvimento Sexual/diagnóstico , Inibidores do Crescimento/deficiência , Inibidores do Crescimento/genética , Humanos , Mutação , Receptores de Superfície Celular/genética , Síndrome , Hormônios Testiculares/deficiência , Hormônios Testiculares/genéticaRESUMO
Müllerian duct regression in male embryos is due to early production by fetal Sertoli cells of anti-Müllerian hormone, a homodimeric protein of the transforming growth factor- beta superfamily. In mammals, both female Müllerian ducts develop into the uterus and Fallopian tubes, whereas in birds, the right oviduct does not develop. To gain insight into sex differentiation in birds, we have cloned the cDNA for chick anti-Müllerian hormone using antibodies raised against the partially purified protein. Expression cloning was required because of the lack of cross-hybridization between mammalian and chick anti-Müllerian hormone DNA. The chick DNA and protein are significantly longer, due to insertions that abolish nucleotide homology, except in the cDNA coding for the C-terminal, bioactive part of the protein. Nevertheless, the general structure of the gene, sequenced from the transcription initiation to the polyadenylation site, and the main features of the protein are conserved between the chick and mammals. The chick anti-Müllerian hormone gene is expressed at high levels in Sertoli cells of the embryonic testes and in lower amounts in both ovaries, higher levels being reached on the left side after 10 days of incubation.
Assuntos
Expressão Gênica , Glicoproteínas , Inibidores do Crescimento/biossíntese , Inibidores do Crescimento/química , Hormônios Testiculares/biossíntese , Hormônios Testiculares/química , Sequência de Aminoácidos , Animais , Hormônio Antimülleriano , Sequência de Bases , Northern Blotting , Bovinos , Embrião de Galinha , Galinhas , Clonagem Molecular , Sequência Conservada , Primers do DNA , DNA Complementar , Humanos , Íntrons , Masculino , Mamíferos , Camundongos , Dados de Sequência Molecular , Ductos Paramesonéfricos/fisiologia , Técnicas de Cultura de Órgãos , Reação em Cadeia da Polimerase , Ratos , Homologia de Sequência de Aminoácidos , Testículo/embriologia , Testículo/metabolismo , Transcrição GênicaRESUMO
Anti-Müllerian hormone (AMH) and its receptor are involved in the regression of Müllerian ducts in male fetuses. We have now cloned and mapped the human AMH receptor gene and provide genetic proof that it is required for AMH signalling, by identifying a mutation in the AMH receptor in a patient with persistent Müllerian duct syndrome. The mutation destroys the invariant dinucleotide at the 5' end of the second intron, generating two abnormal mRNAs, one missing the second exon, required for ligand binding, and the other incorporating the first 12 bases of the second intron. The similar phenotypes observed in AMH-deficient and AMH receptor-deficient individuals indicate that the AMH signalling machinery is remarkably simple, consisting of one ligand and one type II receptor.